NASDAQ: TARAProtara Therapeutics Inc Stock
$2.41-0.07 (-2.82%)
Updated Nov 2, 2026
TARA Price
$2.41
Fair Value Price
$1.08
Market Cap
$142.42M
52 Week Low
$2.28
52 Week High
$7.82
P/E
-1.77x
P/B
0.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$70.02M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$66M
Beta
1.1
Next Earnings
Nov 9, 2026
Ex-Dividend
N/A
Next Dividend
N/A
TARA Overview
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TARA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TARA
Ranked#377 of 452
Ranked#377 of 452
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $961.26 | A | |
| $10.18 | A | |
| $361.27 | A |
Be the first to know about important TARA news, forecast changes, insider trades & much more!
TARA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TARA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TARA ($2.41) is overvalued by 122.98% relative to our estimate of its Fair Value price of $1.08 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TARA ($2.41) is not significantly undervalued (122.98%) relative to our estimate of its Fair Value price of $1.08 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TARA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TARA due diligence checks available for Premium users.
Valuation
TARA fair value
Fair Value of TARA stock based on Discounted Cash Flow (DCF)
Price
$2.41
Fair Value
$1.08
Overvalued by
122.98%
TARA ($2.41) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TARA ($2.41) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TARA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TARA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.77x
Industry
17.34x
Market
44.91x
TARA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.88x
Industry
5.11x
TARA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TARA's financial health
Profit margin
Revenue
$0.0
Net Income
-$21.7M
Profit Margin
0%
TARA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$176.1M
Liabilities
$14.8M
Debt to equity
0.09
TARA's short-term assets ($146.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TARA's short-term assets ($146.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TARA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TARA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.4M
Investing
$17.8M
Financing
-$26.0k
TARA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TARA vs Biotech Stocks
Protara Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.